original articlesearly drug developmentWhat hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)
early drug development
Under a Creative Commons license
open access
Key words
ETV6-NTRK3
TrkC
mammary analogue secretory carcinoma
entrectinib
Cited by (0)
Copyright © 2016 THE AUTHORS. Published by Elsevier Ltd.